ADAR1 Capital Management »

TherapeuticsMD shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of TherapeuticsMD (TXMD) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in TherapeuticsMD

Tip: Access up to 7 years of quarterly data

All positions including TherapeuticsMD held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in TherapeuticsMD by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $623k 272k 2.29
2023-12-31 $612k 272k 2.25

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding TherapeuticsMD

Rubric Capital Management
Clearline Capital
Tejara Capital
Vanguard Group
Morgan Stanley
BlackRock
BlackRock
Geode Capital Management
Bridgeway Capital Management
State Street Corporation
Northern Trust
Two Sigma Securities
J. Goldman & Co
Citadel Advisors
Tower Research Capital

View all funds holding TherapeuticsMD